About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

India Grants Patent for Gileadís Hepatitis C Drug

by Reshma Anand on May 11, 2016 at 12:57 PM
Font : A-A+

India Grants Patent for Gileadís Hepatitis C Drug

US pharmaceutical giant Gilead has obtained a patent for its Hepatitis C drug from India. This patent could potentially stop affordable copies reaching millions of people in other countries.

The drug, Sovaldi, which costs $1,000 a pill in the United States, was rejected for a patent in January 2015 following opposition by health activists who said the science was not sufficiently new.

Advertisement


But after an appeal by Gilead, the Indian Patent Office granted its application for the drug, chemically known as sofosbuvir, saying it found the "compounds novel, inventive and patentable".

"This decision underlines the scientific innovation involved in the development of this breakthrough treatment for chronic Hepatitis C," Gilead spokesman Nick Francis said in a statement.
Advertisement

The ruling will not immediately affect patients in India, where several firms are licensed by Gilead to produce low-cost versions of sofosbuvir for sale in developing countries.

But drug access campaigners slammed the decision, saying it could prevent the export of raw materials to other countries seeking to make the drug that some have hailed as a miracle cure.

"We know there are millions of people in other countries who now won't have affordable access because of this decision," said Leena Menghaney, South Asia head of the Medecins Sans Frontieres' Access Campaign.

"It will block a sustainable supply of key raw materials needed to produce the drug in countries like Egypt, Bangladesh and Pakistan, and hence affect production by new suppliers," she said.

Tahir Amin, co-founder of the group Intellectual Property, Initiative for Medicines, Access & Knowledge said the patent office's decision was "flawed".

"(It) ignores the scientific facts and fails to uphold the standards of Indian patent law to ensure only new inventions are patented," he said.

India earned a nickname as the pharmacy to the developing world for its tough stance on patents, taking a view that they should be granted only for major innovations, not updates to existing compounds.

More than 130 million people live with chronic Hepatitis C worldwide, according to the World Health Organization, and 500,000 die each year from related liver diseases.

Source: AFP
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test Your Knowledge on Kidney
World Disability Day 2022 - The Role of Innovative Transformation
Diet and Oral Health: The Sugary Connection May Become Sour
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Hepatitis A Hepatitis B Vasculitis Signature Drug Toxicity Silent Killer Diseases Liver Drugs Banned in India Aplastic Anemia Hepatitis C 

Most Popular on Medindia

Selfie Addiction Calculator Color Blindness Calculator Accident and Trauma Care Hearing Loss Calculator The Essence of Yoga Loram (2 mg) (Lorazepam) A-Z Drug Brands in India Pregnancy Confirmation Calculator Nutam (400mg) (Piracetam) Sanatogen
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

India Grants Patent for Gileadís Hepatitis C Drug Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests